Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu01:29

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

83
Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
83
ATP Synthase: Mechanism01:48

ATP Synthase: Mechanism

18.2K
In animals, the mitochondrial F1F0 ATP synthase is the key protein that synthesizes ATP molecules through a complex catalytic mechanism. While the nuclear genome encodes the majority of ATP synthase subunits, the mitochondrial genome encodes some of the enzyme's most critical components. The formation of this multi-subunit enzyme is a complex multi-step process regulated at the level of transcription, translation, and assembly. Defects in one or more of these steps can result in decreased...
18.2K
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

61
Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
61
Pharmacogenetics of Phase II Enzymes: N-acetyltransferase, Thiopurine S-methyltransferase, UDP-glucuronosyltransferase01:27

Pharmacogenetics of Phase II Enzymes: N-acetyltransferase, Thiopurine S-methyltransferase, UDP-glucuronosyltransferase

55
Phase II biotransformation reactions are essential for detoxifying and eliminating xenobiotics, including many pharmaceutical compounds. These reactions typically involve conjugation, the covalent attachment of polar endogenous groups such as glucuronic acid, sulfate, methyl, or acetyl moieties to functional groups introduced during Phase I metabolism. The resulting conjugates are more water-soluble, enabling efficient renal or biliary excretion.The major classes of Phase II enzymes include...
55
Pharmacogenetics of Drug Transporters: P-Glycoprotein and Solute Carrier Transporters01:16

Pharmacogenetics of Drug Transporters: P-Glycoprotein and Solute Carrier Transporters

90
The pharmacogenetics of drug transporters is increasingly recognized as a critical factor influencing interindividual variability in drug absorption, distribution, and elimination. These membrane-bound proteins regulate drugs' movement across cellular barriers by actively pumping them out (efflux) or facilitating their uptake (influx). Among the major transporter families, ATP-binding cassette (ABC) and solute carrier (SLC) transporters play particularly prominent roles. Genetic polymorphisms...
90
Pharmacogenetics of Phase I Enzymes: Cytochrome P450 Isozymes01:28

Pharmacogenetics of Phase I Enzymes: Cytochrome P450 Isozymes

87
Cytochrome P450 (CYP450) enzymes are a superfamily of heme-containing monooxygenases that play a pivotal role in Phase I drug metabolism by catalyzing oxidation and reduction reactions.These enzymes transform lipophilic xenobiotics into more hydrophilic metabolites, facilitating subsequent Phase II conjugation and eventual excretion. The CYP450 family is classified into families (e.g., CYP1–CYP3) and subfamilies (e.g., CYP2A, CYP2C), based on amino acid sequence homology.CYP450...
87

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Physical health and sleep quality as mediators of the stress-cognitive function pathway in community-dwelling older adults.

International psychogeriatrics·2026
Same author

Respirometry-Based Screening of Marine Natural Products Identifies Leptochelin A as a Novel Modulator of Mitochondrial Function.

Oxidative medicine and cellular longevity·2026
Same author

Serum metabolic signatures of cognitive resilience in a longitudinal aging cohort.

bioRxiv : the preprint server for biology·2026
Same author

An FDA-Approved Tenofovir Alafenamide-Based Antiretroviral Therapy Reduces Biological Age in Healthy Adults: First Human Proof-of-Concept for Retrotransposon-Targeted Gerotherapeutics.

medRxiv : the preprint server for health sciences·2026
Same author

A multi-layered approach to elucidate mechanisms of physical function in response to rehabilitation in heart failure with preserved ejection fraction.

medRxiv : the preprint server for health sciences·2026
Same author

Effects of body composition on age- and sex-related differences in resting metabolic rate from a healthy aging cohort.

Experimental gerontology·2026

Related Experiment Video

Updated: Mar 12, 2026

Assessment of Mitochondrial Functions and Cell Viability in Renal Cells Overexpressing Protein Kinase C Isozymes
15:43

Assessment of Mitochondrial Functions and Cell Viability in Renal Cells Overexpressing Protein Kinase C Isozymes

Published on: January 7, 2013

18.7K

APOL1 Renal-Risk Variants Induce Mitochondrial Dysfunction.

Lijun Ma1,2, Jeff W Chou2,3, James A Snipes4

  • 1Department of Internal Medicine, Section on Nephrology, lima@wakehealth.edu bfreedma@wakehealth.edu.

Journal of the American Society of Nephrology : JASN
|November 9, 2016
PubMed
Summary
This summary is machine-generated.

The APOL1 G1 and G2 variants, linked to kidney disease in Black individuals, impair mitochondrial function. This dysfunction, affecting cellular respiration and NAD biosynthesis, precedes other disease indicators, highlighting its central role.

Keywords:
APOL1chronic kidney diseasemitochondria

More Related Videos

Targeted Next-generation Sequencing and Bioinformatics Pipeline to Evaluate Genetic Determinants of Constitutional Disease
09:34

Targeted Next-generation Sequencing and Bioinformatics Pipeline to Evaluate Genetic Determinants of Constitutional Disease

Published on: April 4, 2018

35.0K
Isolation, Characterization, And High Throughput Extracellular Flux Analysis of Mouse Primary Renal Tubular Epithelial Cells
09:40

Isolation, Characterization, And High Throughput Extracellular Flux Analysis of Mouse Primary Renal Tubular Epithelial Cells

Published on: June 20, 2018

18.7K

Related Experiment Videos

Last Updated: Mar 12, 2026

Assessment of Mitochondrial Functions and Cell Viability in Renal Cells Overexpressing Protein Kinase C Isozymes
15:43

Assessment of Mitochondrial Functions and Cell Viability in Renal Cells Overexpressing Protein Kinase C Isozymes

Published on: January 7, 2013

18.7K
Targeted Next-generation Sequencing and Bioinformatics Pipeline to Evaluate Genetic Determinants of Constitutional Disease
09:34

Targeted Next-generation Sequencing and Bioinformatics Pipeline to Evaluate Genetic Determinants of Constitutional Disease

Published on: April 4, 2018

35.0K
Isolation, Characterization, And High Throughput Extracellular Flux Analysis of Mouse Primary Renal Tubular Epithelial Cells
09:40

Isolation, Characterization, And High Throughput Extracellular Flux Analysis of Mouse Primary Renal Tubular Epithelial Cells

Published on: June 20, 2018

18.7K

Area of Science:

  • Genetics
  • Molecular Biology
  • Nephrology

Background:

  • The APOL1 gene has variants (G1, G2) associated with increased kidney disease risk in individuals of African descent.
  • The precise mechanisms by which these APOL1 risk variants contribute to kidney disease pathogenesis remain incompletely understood.

Purpose of the Study:

  • To investigate the molecular pathways through which APOL1 G1 and G2 variants contribute to kidney disease.
  • To determine the role of mitochondrial dysfunction in APOL1-associated nephropathy.

Main Methods:

  • Established doxycycline-inducible HEK293 cell lines expressing APOL1 G0 (reference), G1, or G2 variants.
  • Utilized global gene expression profiling (Illumina HT-12 v4, Affymetrix HTA 2.0) and bioinformatics analyses.
  • Performed immunoblotting, immunofluorescence, and cellular respiration assays to validate findings.

Main Results:

  • Overexpression of APOL1 G1/G2 variants in HEK293 cells led to significant mitochondrial dysfunction, including reduced respiration rates and membrane potential.
  • Impaired mitochondrial function was observed prior to intracellular potassium depletion or decreased cell viability.
  • Downregulation of nicotinate phosphoribosyltransferase (NAD biosynthesis) was identified in cells with APOL1 risk variants, correlating with mitochondrial dysfunction.

Conclusions:

  • Mitochondrial dysfunction is a key mechanism in the pathogenesis of APOL1-associated kidney disease.
  • APOL1 risk variants directly impair cellular energy metabolism and mitochondrial integrity.
  • Targeting mitochondrial pathways may offer therapeutic strategies for APOL1 nephropathy.